ACE2 as a potential therapeutic target for pandemic COVID-19 (original) (raw)
* Corresponding authors
a National Institute of Pharmaceutical Education and Research (NIPER), Dept. of Pharmaceuticals, Ministry of Chemicals and Fertilizers, Govt. of India, Balanagar, Hyderabad-500 037, Telangana, India
E-mail: bhaswatichatterjee@yahoo.com, bhaswati@niperhyd.ac.in
b Centre for Cellular and Molecular Biology, Uppal Road, Hyderabad-500007, India
E-mail: sst@ccmb.res.in
Tel: +91-40-27192865, +91-40-27192505
Abstract
SARS-CoV-2 virus invades the host through angiotensin-converting enzyme 2 (ACE2) receptors by decreasing the ACE2 expression of the host. This disturbs the dynamic equilibrium between the ACE/Ang II/AT1R axis and ACE2/Ang (1–7)/Mas receptor axis. Therefore, the clinically approved drugs belonging to (i) angiotensin converting enzyme (ACE) inhibitors such as captopril, and enalaprilat, (ii) angiotensin-receptor blockers (ARBs) such as losartan, candesartan, olmesartan, azilsartan, irbesartan, and telmisartan and (iii) the combination of ACE inhibitors and ARBs such as losartan with lisinopril and captopril with losartan, and (iv) recombinant ACE2, were studied for their ability to activate ACE2 in different medical conditions including hypertension, inflammation, cardiovascular, renal and lung diseases. These clinically approved drugs were found to activate ACE2 that had been downregulated in different medical conditions including hypertension, inflammation, cardiovascular, renal and lung diseases. Therefore, these drugs may be repurposed to re-activate the downregulated ACE2 of COVID-19 patients. These drugs either alone or in combination may be repurposed as prophylactics and therapeutics against SARS-CoV-2 virus.
- This article is part of the themed collections:Coronavirus articles - free to access collection and 2020 Reviews in RSC Advances
This article is Open Access
Please wait while we load your content... Something went wrong. Try again?
Article information
DOI
https://doi.org/10.1039/D0RA08228G
Article type
Review Article
Submitted
25 Sep 2020
Accepted
26 Oct 2020
First published
01 Nov 2020
This article is Open Access
Download Citation
RSC Adv., 2020,10, 39808-39813
Permissions
ACE2 as a potential therapeutic target for pandemic COVID-19
B. Chatterjee and S. S. Thakur,RSC Adv., 2020, 10, 39808DOI: 10.1039/D0RA08228G
This article is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported Licence. You can use material from this article in other publications, without requesting further permission from the RSC, provided that the correct acknowledgement is given and it is not used for commercial purposes.
To request permission to reproduce material from this article in a commercial publication, please go to the Copyright Clearance Center request page.
If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.
If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party commercial publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.
Read more about how to correctly acknowledge RSC content.